Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Curr Colorectal Cancer Rep. 2019 Mar 20;15(2):61–69. doi: 10.1007/s11888-019-00430-6

Table 1.

Molecular Subtypes of Colorectal Cancer and Select Treatment Options

CRC Subtypes Select Treatment Options
RAS/RAF wild-type, microsatellite stable cetuximab or panitumumab
KRAS/NRAS mutant, microsatellite stable cytotoxic chemotherapy, no current targeted therapy options
MSI-H/MMR deficient pembrolizumab or nivolumab or nivolumab in combination with ipilimumab
BRAF V600 mutant vemurafenib, cetuximab and irinotecan or MEK plus BRAF inhibitor in combination with cetuximab or panitumumab
HER2 amplified trastuzumab in combination with pertuzumab or lapatinib
NTRK fusion Larotrectinib
PIK3CA mutant, RAS/RAF wild-type PI3K inhibitor clinical trials